Figure 2.

Intratumoral cDC1 Accumulation Depends on NK Cells

(A) Quantification of tumor-infiltrating lymphocytes in control or Ptgs1/Ptgs2^−/− BRAF^V600E tumors (day 4).

(B) Image of a Ptgs1/Ptgs2^−/− BRAF^V600E tumor. Insets show colocalization of CD103⁺ cDC1 and NK1.1⁺ cells in multicellular clusters. Scale bar, 50 μm. The dashed line indicates the tumor margin. Data are representative of 6 tumors from two experiments.

(C) Distance analysis based on (B). Data represent quantification across 6 images from 6 tumors.

(D) Image of a tumor from a MMTV-PyMT mouse. Insets show colocalization of CD103⁺ cDC1 and NK1.1⁺ cells. Scale bar, 100 μm. Data are representative of 4 independent experiments.

(E) Distance analysis based on (D). Data represent quantification across 8 images from 4 tumors.

(F and G) Quantification of cDC1 in control or Ptgs1/Ptgs2^−/− BRAF^V600E tumors 4 days after s.c. inoculation of 2 × 10⁶ tumor cells into WT mice, Rag1^−/− mice, or Rag2^−/−Il2rg^−/− mice with or without NK cell depletion.

(H) Quantification of NK cells in control or Ptgs1/Ptgs2^−/− BRAF^V600E tumors 4 days after inoculation of WT mice or Batf3^−/− mice.

(I) Effect of NK cell depletion on the growth of Ptgs1/Ptgs2^−/− BRAF^V600E tumors in WT or Batf3^−/− mice.

Data shown in (A) and (F)–(I) are pooled from at least two independent experiments with 4–6 mice per group and represented as mean ± SEM; (A), (C), and (E–I): n.s., non-significant, ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001.

See also Figure S2.